The global anti-obesity drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factor augmenting the market growth include a substantial rise in the number of overweight and obese population all over the globe. As per the World Health Organization (WHO), in June 2021, nearly 2.8 million mortalities are attributed to the underlying cause which include overweight or obesity. Adding to this, in 2021, nearly 115 million individuals were suffering from obesity-related ailments in developing countries, as per the same source. Therefore, there is an increased demand for anti-obesity drugs among the global population to maintain normal body weight. Further, looking at the alarming levels of obesity globally, government coupled with the private health organizations are undertaking various global obesity awareness programs. 

Several programs are also conducted to promote maintaining a normal body weight, which, in turn, is driving the growth of the global anti-obesity drugs market. In addition, the rising awareness regarding obesity as an underlying cause of various other ailments and chronic diseases including hypertension, CVD, and diabetes, among others, is further likely to drive the growth of anti-obesity drugs. As per the International Diabetes Federation (IDF), the total adult population in the US with diabetes was 31 million in 2019 while in Canada, it was 2.8 million. The US has the largest population of children and adolescents with type 1 diabetes (175,900). Majority of these cases are the result of obesity being the primary factor. As a result, the demand for anti-obesity treatment is growing significantly across the globe. 

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Drug Mechanism

o By Type

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

    • Competitive Landscape: F. Hoffman La-Roche AG, GlaxoSmithKline plc, Novo Nordisk A/S, among others.

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How are players addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Anti-Obesity Drugs Market Report by Segment

By Drug Mechanism

    • Peripherally Acting Obesity Drugs

    •  Centrally Acting Obesity Drugs

By Type

    • Prescription Drugs

    • OTC Drugs

Global Anti-Obesity Drugs Market Report by Region

North America       

    • US

    • Canada

Europe

    • Germany

    • UK

    • France

    • Spain

    • Italy

    • Rest of Europe

Asia-Pacific    

    • China

    • Japan

    • India

    • Rest of Asia-Pacific

Rest of the World

    • Latin America

    • Middle East and Africa